文献速递炎症性肠病

乌帕替尼与托法替布在溃疡性结肠炎中的比较有效性:美国倾向匹配队列研究

Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A US Propensity-Matched Cohort Study.
PubMed 文献 · Am J Gastroenterol · 2024-07-05

本研究利用TriNetX多机构数据库开展回顾性队列研究,比较乌帕替尼与托法替布在溃疡性结肠炎患者中的有效性。经1:1倾向评分匹配后,乌帕替尼组12个月内需要静脉激素和/或结肠切除术的复合结局风险低于托法替布组(aOR 0.63,95%CI 0.44-0.89),6个月内无显著差异。

要点

  • 12个月内乌帕替尼组复合结局风险低于托法替布组(aOR 0.63,95%CI 0.44-0.89)。
  • 6个月内复合结局风险两组无显著差异(aOR 0.75,95%CI 0.49-1.09)。
  • 12个月内乌帕替尼组结肠切除术风险低于托法替布组(aOR 0.46,95%CI 0.27-0.79)。

核心结论

  • 利用真实世界数据,乌帕替尼与托法替布相比,在溃疡性结肠炎患者中12个月时疾病特异性结局更好。

研究设计与样本

  • 回顾性队列研究,使用TriNetX多机构数据库,比较乌帕替尼与托法替布在溃疡性结肠炎患者中的有效性。
  • 乌帕替尼组526例(平均年龄40.4±16.3岁,女性44.8%,白人76.6%),托法替布组1149例(平均年龄42±17.1岁,女性41.9%,白人76%)。
  • 对人口学特征、合并症、平均血红蛋白、C反应蛋白、白蛋白、钙卫蛋白及既往溃疡性结肠炎药物(包括近期口服或静脉激素使用)进行1:1倾向评分匹配。

主要发现

  • 倾向评分匹配后,6个月内需要静脉激素和/或结肠切除术的复合结局风险两组无显著差异(aOR 0.75,95%CI 0.49-1.09)。
  • 12个月内乌帕替尼组复合结局风险低于托法替布组(aOR 0.63,95%CI 0.44-0.89)。
  • 12个月内静脉激素使用风险两组无差异(aOR 0.70,95%CI 0.48-1.02),但乌帕替尼组结肠切除术风险低于托法替布组(aOR 0.46,95%CI 0.27-0.79)。
  • 敏感性分析中,12个月内乌帕替尼组复合结局风险低于托法替布组(aOR 0.64,95%CI 0.44-0.94),静脉激素使用风险更低(aOR 0.67,95%CI 0.45-0.99),结肠切除术风险更低(aOR 0.49,95%CI 0.26-0.92)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There are limited real-world data comparing the effectiveness of upadacitinib and tofacitinib in patients with ulcerative colitis (UC). METHODS: We conducted a retrospective cohort study using TriNetX, a multi-institutional database, to compare the effectiveness of upadacitinib and tofacitinib in patients with UC. The primary aim was to assess the risk of a composite outcome of hospitalization requiring intravenous steroids and/or colectomy within 6 and 12 months. One-to-one propensity score matching was performed for demographics, comorbid conditions, mean hemoglobin, C-reactive protein, albumin, and calprotectin, and prior UC medications including recent oral or intravenous steroid use between the cohorts. Risk was expressed as adjusted odds ratio (aOR) with 95% confidence intervals (CI). RESULTS: There were 526 patients in the upadacitinib cohort (mean age 40.4 ± 16.3, 44.8% female sex, 76.6% White race) and 1,149 patients in the tofacitinib cohort (mean age 42 ± 17.1, 41.9% female sex, 76% White race). After propensity score matching, there was no significant difference in the risk of the composite outcome of need for intravenous steroids and/or colectomy within 6 months (aOR 0.75, 95% CI 0.49-1.09). However, there was a lower risk of the composite outcome (aOR 0.63, 95% CI 0.44-0.89) in the upadacitinib cohort compared with the tofacitinib cohort within 12 months. There was no difference in the risk of intravenous steroid use (aOR 0.70, 95% CI 0.48-1.02) but lower risk of colectomy (aOR 0.46, 95% CI 0.27-0.79). In sensitivity analysis, there was also a lower risk of the composite outcome (aOR 0.64, 95% CI 0.44-0.94), including lower risk of intravenous steroid use (aOR 0.67, 95% CI 0.45-0.99) and colectomy (aOR 0.49, 95% CI 0.26-0.92) in the upadacitinib cohort compared with the tofacitinib cohort within 12 months. DISCUSSION: This study utilizing real-world data showed that upadacitinib was associated with improved disease-specific outcomes at 12 months compared with tofacitinib in patients with UC.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kochhar GS, Khataniar H, Jairath V, et al. Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A US Propensity-Matched Cohort Study. Am J Gastroenterol. 2024. PMID: 38976357. doi:10.14309/ajg.0000000000002947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。